

بسم الله الرحمن الرحيم


دکتر زهراسادات ثقة الاسلامی

متخصص بیماریهای عفونی و گرمسیری

عضو تیم تخصصی مرکز درمان ناباروری ابن سینا

استادیار دانشگاه علوم پزشکی آزاد

HPV(human papillomavirus)



- Interest in human papillomavirus (HPV) infection began in earnest in the 1980s after Harold zur Hausen postulated that infection with these viruses was associated with **cervical cancer**.
- It is now recognized that HPV infection of the human genital tract is extremely common and causes clinical conditions ranging from **asymptomatic infection** to genital warts (condylomata acuminata); dysplastic lesions and invasive cancers of the anus, penis, vulva, vagina, and cervix; and a subset of oropharyngeal cancers.

PATHOGENESIS

- HPV is a double-stranded **DNA virus**
- HPV's genome consists of an **early (E)** gene region, a **late (L)** gene region
- The E1, E2, E5, E6, and E7 proteins are expressed early in the growth cycle and are necessary for **viral replication** and cellular transformation. The E6 and E7 proteins are responsible for malignant transformation, targeting the human cell-cycle regulatory molecules p53 and Rb (retinoblastoma protein) for degradation, respectively
- Approximately **40 HPV** types are regularly identified in the **anogenital** tract; these types are subdivided into high-risk and low-risk categories depending on the associated risk of cervical cancer

- HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 are carcinogenic in the uterine cervix
- HPV type 16 is particularly virulent and causes 50% of cervical cancers
- HPV types 16 and 18 cause at least 70% of cervical squamous cell carcinomas and 85% of cervical adenocarcinomas.
- HPV types 16 and 18 also cause nearly 90% of anal cancers worldwide
- other HPV-associated cancers include vulvar and vaginal cancer (caused by HPV in 50– 70% of cases), penile cancer (caused by HPV in 50% of cases), and at least 65% of oropharyngeal squamous cell carcinomas (OPSCCs).
- Over the past two decades, an epidemic of OPSCC related to oncogenic HPV infection, primarily HPV type 16, has developed.

- While HPV is the causative agent of several cancers, most attention has focused on **cervical cancer**, which is the **fourth most common cancer in women worldwide**.
- More than **500,000** women are diagnosed and **275,000** die from invasive cervical cancer annually
- Evidence collected over 25 years shows that HPV causes **nearly 100% of cervical cancers**.
- The time from HPV infection to cervical cancer may exceed **20 years**. only **~3–5%** of infected women will ever develop this cancer

- ~40% of young women demonstrate evidence of HPV infection, with peaks during the teens and early twenties, soon after first coital experience.
- The number of lifetime sexual partners correlates with the likelihood of HPV infection and the subsequent risk of HPV-associated malignancy
- Most HPV infections become undetectable after 6–9 months, a phenomenon known as “clearance.”
- with prolonged followup and frequent sampling, the same HPV types may again be detected months or even years later. It is still debated whether such episodic detection indicates viral latency followed by reactivation or represents reinfection with an identical HPV type

Overview: HPV and Genital Warts

Causative Agent

Human Papillomavirus (HPV) types **6 and 11** cause **90% of genital warts** (condyloma acuminatum). These are classified as low-risk HPV types — they do not carry oncogenic potential and are distinct from the high-risk types (16, 18) associated with cervical and anogenital cancers.

Prevalence

HPV is the **most common sexually transmitted infection** globally. Over **80% of sexually active unvaccinated individuals** will acquire HPV infection at some point in their lifetime, making population-level exposure nearly universal in the absence of vaccination.

Natural History

In approximately **9 out of 10 cases**, HPV resolves spontaneously within **1–2 years** without intervention or health sequelae. Persistent infection — particularly in immunocompromised hosts — is the primary driver of wart development and recurrence.

Incubation Period

Genital warts may appear as early as **6 weeks** after initial infection or as late as **6 months or more**. Latent infection with delayed expression is clinically significant — patients may be unaware of prior exposure at the time of presentation.

90%

Caused by HPV 6 & 11

Low-risk, non-oncogenic types

>80%

Lifetime Exposure

Sexually active, unvaccinated adults

90%

Spontaneous Clearance

Within 1–2 years in immunocompetent hosts

6 wks

Earliest Wart Onset

Post-exposure; may be delayed months to years

Risk Factors for Acquisition and Transmission

Behavioral Risk Factors

→ Multiple Sexual Partners

Each additional partner incrementally increases cumulative HPV exposure risk. This is the strongest modifiable behavioral risk factor.

→ Early Sexual Debut

Younger age at first intercourse is associated with increased susceptibility, likely due to cervical ectropion in younger females and higher partner turnover.

→ Inconsistent Barrier Use

Irregular or absent condom use significantly increases transmission risk. However, condoms reduce — but do not eliminate — risk due to incomplete coverage of infected skin.

→ Concurrent STIs

Co-infection with herpes simplex virus or other pathogens that disrupt mucosal integrity can amplify HPV acquisition and shedding.

Host-Related Risk Factors

Immunosuppression

HIV/AIDS, uncontrolled diabetes, or use of immunosuppressive medications (e.g., post-transplant therapy, systemic corticosteroids) significantly increase the risk of persistent infection and florid wart proliferation.

Pregnancy

Hormonal changes and relative immunomodulation during pregnancy may accelerate wart proliferation. Additionally, large wart burden near delivery may raise consideration of vertical transmission risk.

Tobacco & Alcohol Use

Both substances impair local and systemic immune surveillance, reducing the host's ability to clear HPV infection spontaneously and increasing duration of infectivity.

Transmission

- **Close personal contact**, especially within the family and school class, is likely to be important for the transmission of most cutaneous warts. **Minor trauma** at the site of inoculation may also be important, as suggested by the high frequency of disease among meat handlers
- Evidence that anogenital warts are **sexually** transmitted includes the observations that the age of onset is similar to that in other sexually transmitted diseases (STDs)
- In addition, patients with anogenital warts often have other **concomitant STDs** or a history of such infections.
- a large number of lifetime, present, or **recent sexual partners**; the frequency of **sex or other intimate skin-to-skin contact**; and the sexual histories or behavior of **sex partners** are risk factors of genital HPV transmission, whereas **circumcision** is protective, as with human immunodeficiency virus (HIV) and herpes simplex virus

- There are multiple pathways for HPV transmission across different mucosal sites. They include **autoinoculation** within one host, and transmission **between individuals**.
- Interindividual transmission includes perinatal transmission, sexual transmission by various techniques of orogenital sex, and indirect transmission through contact with hand

Autoinoculation

- **Autoinoculation** between the genital and oral or anal sites could occur through intermediate contact with the hands or through virus shedding in the anogenital region
- Women with proven cervical HPV infection, cervical dysplasia or invasive cancer have a higher prevalence of HPV in **oral samples**, indicating a relationship between such infections but the correlation between cervical and oral colonisation by HPV is **low** Therefore simultaneous testing of oropharyngeal and cervical HPV infection does not seem promising as future screening strategy
- Two different studies, one held in a university and one in a hospital, have revealed an abundance of HPV DNA on the **fingers of infected persons**, highlighting inadequate or non-existing hand hygiene . Studies demonstrated DNA HPV **under fingernails** of individuals with genital warts, as well as in their **underwear** .

Perinatal transmission

- **High prevalence** (44.9%) of HPV at prenatal testing in young pregnant women was followed by frequently detected HPV in placenta samples (14%) and in newborns (11.2%).
- Although the exact mode of transmission is not well understood, oral HPV prevalence ranged from 10% to 30% among newborns born to HPV-positive mothers
- **Vertical transmission** may occur in utero through ascending infection (transplacental transmission), during vaginal delivery, at caesarean section or in periconceptual transmission from the **male sexual partner**
- HPV can be transmitted vertically to neonates through breast feeding
- Perinatal transmission of LR-HPV to neonates at birth has been confirmed to be associated with **recurrent respiratory papillomatosis** (RRP) development.

- **Contaminated equipment** in gynecological examination rooms has been an interesting topic of evaluation in HPV infection routes.
- HPVs are very **steady** viruses, repellant to heat, and drying [they show 30% infectivity after seven days of dehydration]
- The viruses are apt to live for days on surfaces, clothing, frequently used gynecological equipment, and fomites
- A study evaluating this particular HPV transmission pattern has detected HPV DNA in 32 out of 179 (**17.9%**) samples collected from gynecological equipment.
- A study has also revealed that **~9.4% of gloves** were contaminated, and **colposcopy rooms** have a higher risk of being infected with HPV than outpatient offices

- Transvaginal ultrasound probes are protected with condoms, which act as a physical barrier to contamination (**the risk of condom rupture is ~0.9-5%**)
- Another study revealed, by collecting high-risk HPV DNA samples from transvaginal ultrasound, **after low-level disinfection and probe cover**, that a considerable number of probes were contaminated: Probes (3%) tested positive in post-examination samples and 1.9% in pre-examination samples
- Most individuals are not aware they are infected because they are **asymptomatic**

Everyday hygiene measures

- medical equipments after conventional disinfection have found them to still be positive, especially for **type 16**
- HPV 16 was found **resistant to alcohol-based** disinfection (ethanol and isopropanol), but sensitive to hypochlorite and high concentrations of peracetic acid-silver-based disinfectant
- **New disinfection protocols for healthcare equipment are necessary.**



<http://www.ijwhr.net>



doi 10.15296/ijwhr.20

Open Access

Original A



IJWHR

International Journal of Women's Health and Reproduction Sciences

Vol. 13, No. 1, January 2025, 13-17

ISSN 2330-4456

The Association Between Pubic and External Genitalia Hair Removal by Laser Devices and Human Papillomavirus (HPV) Infection

Manizheh Sayyah-Melli¹, Shabnam Yaghoubi Kondelaji^{1*}, Parvin Mostafa-Gharabaghi¹, Mehri Jafari Shol
Behrooz Shokouhi¹, Vahideh Rahmani¹, and Maryam Vaezi¹

Conclusions: Laser hair removal **was positively** associated with positive HPV transmission. However, it was recommended that further studies with greater sample sizes should be carried out to determine if the pubic hair removal by laser devices increased the HPV transmission risk

The risk of HPV transmission during laser hair removal sessions is **theoretically possible but extremely low**, and standard infection control practices—including proper equipment sterilization and use of protective barriers—effectively mitigate this minimal risk.

Confirmed Transmission Routes

Genital HPV types 6 and 11 are transmitted **exclusively through direct contact** with infected epithelial surfaces. The following routes are supported by robust epidemiological and clinical evidence.

1 **Vaginal Intercourse**
The primary transmission route. Direct skin-to-skin contact with infected genital tissue during penetrative sex enables viral transfer across mucosal surfaces and micro-abrasions.

2 **Anal Intercourse**
Both receptive and insertive anal contact with an infected partner carry transmission risk. Perianal and intra-anal warts are common presentations following this route.

3 **Oral Sex**
Contact between the mouth, lips, or tongue and infected genital tissue can transmit HPV in both directions — from genitals to oral cavity and vice versa when oral lesions are present.

4 **Asymptomatic Shedding**
Critically, a person with HPV can transmit the infection even when **no visible warts are present**. Subclinical viral shedding is well-documented and is a major driver of population-level transmission.

5 **Non-Penetrative Genital Contact**
Genital-to-genital skin contact without penetration is sufficient for transmission. Condom use does not eliminate this risk entirely, as uncovered areas may remain in contact.

6 **Vertical Transmission**
Mother-to-neonate transmission can occur during vaginal delivery. This is a **rare** but recognized route; neonatal exposure may result in recurrent respiratory papillomatosis (laryngeal papillomatosis) in affected infants.

❏ All confirmed transmission routes require **direct contact** with infected epithelial or mucosal tissue. There is no documented evidence of airborne, bloodborne, or fomite-mediated transmission of genital HPV types.

What Does *NOT* Transmit Genital Warts

This is a critical area for patient counseling. Multiple non-sexual routes are commonly feared by patients and their household contacts. The evidence consistently shows **no transmission risk** through the following:

Toilet Seats

HPV cannot survive on non-living, non-porous surfaces. No transmission risk from shared restroom facilities.

Pools & Bathing

Chlorinated water and soap inactivate the virus. No documented transmission through shared swimming or bathing water.

Handshakes & Hugging

Intact skin is an effective barrier. Casual physical contact carries no transmission risk for genital HPV types.

Towels & Clothing

Virus requires direct contact with mucous membranes or abraded skin. Transfer via inanimate objects is not supported by evidence.

Mouth-to-Mouth Kissing

Oral HPV transmission requires direct contact with infected oral or genital tissue. Saliva alone does not transmit genital HPV types 6 or 11.

Utensils & Glasses

Saliva does not carry genital HPV strains. Sharing eating or drinking utensils poses no transmission risk.

Respiratory Droplets

HPV is not an airborne pathogen. Coughing, sneezing, or breathing near an infected individual carries no risk of transmission.

Blood Transfusion

No documented cases of HPV transmission via blood products. Blood transfusion is not a recognized route for genital HPV.

 **Clinical Counseling Point:** Patients living with infected household members — including children, parents, or roommates — face **no transmission risk** through ordinary daily activities. Clearly communicating this reduces stigma and patient anxiety.

Summary: Transmission vs. Non-Transmission

A concise clinical reference for patient counseling and documentation. All confirmed transmission routes involve **direct sexual contact**; no casual or environmental route has been documented.

✔ TRANSMITS Genital Warts	✗ Does NOT Transmit Genital Warts
Vaginal intercourse (skin-to-skin mucosal contact)	Toilet seats (virus does not survive on non-living surfaces)
Anal intercourse (receptive and insertive)	Swimming pools or shared bathing water
Oral sex (mouth-to-genital and genital-to-mouth)	Shared towels or clothing (indirect contact insufficient)
Genital-to-genital contact without penetration	Handshakes and hugging (intact skin is a complete barrier)
Asymptomatic shedding (no visible warts required)	Casual household contact (no risk without sexual activity)
Vertical transmission during vaginal delivery (rare)	Mouth-to-mouth kissing (saliva alone does not transmit genital HPV)
	Shared utensils or drinking glasses
	Respiratory droplets (HPV is not airborne)
	Blood transfusion (no documented bloodborne cases)

📌 **Bottom Line for Counseling:** If it doesn't involve direct contact between genital, anal, or oral mucosal surfaces — it does not transmit genital warts. This boundary should be communicated clearly and consistently to all patients.

TREATMENT

- **None of treatment** modalities has been proven to eliminate HPV from tissue adjacent to the destroyed and infected tissue.
- **Treatment efficacies are limited by frequent recurrences**, presumably due to **reinfection** from an infected partner, **reactivation** of latent virus, or **autoinoculation** from nearby infected cells.
- The goals of treatment include prevention of **viral transmission**, **eradication of premalignant lesions**, and **reduction of symptoms**
- Therapies are generally successful in eliminating **visible lesions and grossly diseased tissue**

THERAPEUTIC OPTIONS

- **Imiquimod** (5 or 3.75% cream) is a patient-applied topical **immunomodulatory agent thought to activate immune cells** by binding to a Toll-like receptor that leads to an inflammatory response. Imiquimod 5% cream is applied to genital warts at **bedtime three times per week for up to 16 weeks**.
- Warts are cleared in **~56% of patients, more often in women than in men**; recurrence rates approach **13%**.
- **Local inflammatory side effects** are common.
- Imiquimod should not be used to treat vaginal, cervical, or anal lesions.
- The safety of imiquimod during **pregnancy** has not been established.

- **Interferon** Recombinant interferon α is used for **intralesional treatment of genital warts, including perianal lesions**.
- Adverse events include headache, nausea, vomiting, fatigue, and myalgia.
- Interferon therapy is **costly** and should be reserved for **severe** cases
- Interferon should not be used to treat vaginal, cervical, or anal lesions.

- **Cryotherapy** (liquid nitrogen treatment) for HPV associated lesions causes **cellular death**.
- Genital warts usually disappear after **two or three** weekly sessions but often **recur**.
- Cryotherapy, which is **nontoxic** and is not associated with **significant adverse reactions**, can also be used for diseased cervical tissue. Local **pain** occurs frequently.
- **Surgical Methods** Exophytic lesions can be surgically removed after intradermal injection of 1% lidocaine

- . **Laser Therapy** Efficacy for genital lesions is at least equal to that of other therapies (60–90%), with **low recurrence rates (5–10%)**. Complications include **local pain, vaginal discharge, periurethral swelling, and penile or vulvar swelling**.
- Laser therapy has also been used successfully for **cervical dysplasia and anal disease caused by HPV**.

TABLE 198-1 Recommended Treatments for Genital Warts Caused by Human Papillomavirus^a

TREATMENT	IMQUIMOD	CRYOTHERAPY	INTERFERON	SURGICAL REMOVAL	LASER
Effectiveness	Good	Good	Good	Excellent	Excellent
Recurrence	Frequent	Frequent	Frequent	Frequent	Frequent
Adverse effects	Frequent, mild to moderate	Mild, well tolerated	Frequent, moderately severe	Mild, well tolerated	Mild to moderate, well tolerated
Availability	Fair	Good	Fair	Good	Fair
Cost	Expensive	Inexpensive	Very expensive	Moderately expensive	Very expensive

Prevention Strategies

Prevention of genital HPV infection and associated warts relies on a **layered approach**, combining immunization, behavioral modification, and clinical surveillance.




HPV Vaccination

The most effective preventive intervention. Current 9-valent vaccine (Gardasil 9) protects against HPV types **6, 11, 16, 18**, and five additional high-risk types. Recommended for all individuals aged 9–26 and shared decision-making for ages 27–45.




Barrier Methods

Consistent condom use reduces transmission risk; evidence on **complete prevention is conflicting** as HPV can infect areas not covered by condoms. Dental dams are recommended for oral sex to reduce bidirectional mucosal exposure.



Cervical & Anal Screening

Pap smears and co-testing with HPV assays detect high-risk HPV-associated dysplasia. Anal Pap testing is recommended for **MSM, HIV-positive, and other immunocompromised patients** at elevated risk for anal carcinoma.



Patient Education

Counsel patients on asymptomatic transmission, the distinction between oncogenic and non-oncogenic HPV types, the limits of condom protection, and the recommendation for vaccination regardless of prior HPV exposure history.

HPV Vaccines

- The development of HPV vaccines effective in preventing infection and HPV-associated disease represents a major development in the past decade
- The vaccines **use virus-like particles** (VLPs) that consist of the HPV L1 major capsid protein.
- **BIVALENT VACCINE** (CERVARIX) The bivalent HPV vaccine contains L1 VLPs of HPV types 16 and 18 and is marketed under the name of Cervarix .
- It is administered by intramuscular injection three times (months 0, 1, and 6)
- Vaccine efficacy related to HPV 16 or HPV 18 was 94.9% (95% confidence interval [CI], 87.7–98.4%) against CIN 2 or worse; 91.7% (95% CI, 66.6–99.1%) against CIN 3 or worse; and 100% (95% CI, –8.6– 100%) against adenocarcinoma in situ (AIS)

- **Injection-site** adverse events (pain, redness, and swelling) and **systemic** adverse events (fatigue, headache, and myalgia) were reported more frequently in the HPV vaccine
- **new-onset chronic disease, or medically significant conditions** occurred in the same proportion (3.5%) of HPV vaccine recipients and control vaccine recipients
- Cervarix is not currently marketed in the United States.

- **QUADRIVALENT VACCINE (GARDASIL):** The quadrivalent L1 VLP vaccine (HPV types **6, 11, 16, and 18**) is marketed under the name **Gardasil (Merck)**. It is administered intramuscularly three times (months 0, 2, and 6)
- vaccine efficacy against external genital warts was 98.9% (95% CI, 93.7–100%). Vaccine efficacy was 95.2% (95% CI, 87.2–98.7%) against CIN; 100% (95% CI, 92.9–100%) against type 16- or 18- related CIN 2/3 or AIS; and 100% (95% CI, 55.5–100.0%) against type 16- or 18-related vulvar intraepithelial neoplasia grades 2 and 3 (VIN 2/3) and against vaginal intraepithelial neoplasia grades 2 and 3 (VaIN 2/3).
- A larger proportion of young women reported **injection-site adverse** events No statistically significant differences in the incidence of any medical conditions between vaccine and placebo recipients were demonstrated; this result indicated a very high safety profile for the vaccine
- rates of **syncope and venous thrombotic** events were higher with Gardasil than those usually observed with other vaccines.

- While the duration of protection has not been established, no evidence of waning protection has been found after a three-dose series of the quadrivalent HPV vaccine, even after 10 years of follow-up from clinical trials.

NINE-VALENT VACCINE (GARDASIL-9)

- In 2014, the FDA approved a new nine-valent L1 VLP vaccine
- The nine-valent vaccine is marketed under the name Gardasil-9 (Merck).
- It is administered intramuscularly three times (months 0, 2, and 6)
- The nine-valent vaccine targets HPV types 6, 11, 16, and 18 (as well as five additional oncogenic HPV types (31, 33, 45, 52, and 58) .
- HPV types 16 and 18 together cause up to 80% of all cervical cancers worldwide, and worldwide data show that HPV types 31, 33, 35, 45, 52, and 58 are the next most frequently detected types in invasive cervical cancers.

- . Analyses of data from clinical trials suggest that the HPV vaccines may offer limited cross protection against nonvaccine virus types but **cross-protection** is likely to be shorter lived than efficacy against infection and disease caused by vaccine types
- CDC now recommends two doses of HPV vaccine (at **0 and 6–12** months) for persons starting the vaccination series before the fifteenth birthday, as the immunologic response is **rigorous** in this age group.
- Three doses of HPV vaccine (at 0, 1–2, and 6 months) are recommended for persons starting the vaccination series on or **after the fifteenth** birthday and for persons with certain **immunocompromising conditions**, including HIV/AIDS.

RECOMMENDATIONS FOR HPV VACCINATION

- The HPV vaccine should be administered, if possible, before exposure to HPV through sexual activity because the vaccines are preventative against specific HPV types and have **no effect on preexisting, type-specific HPV infections**
- An individual can begin a vaccine series with one HPV vaccine and then **complete the series with another.**
- For those who have completed a vaccination series with the bivalent or quadrivalent vaccine an additional full series (three doses) of vaccination with the **nine-valent vaccine may be given**
- For children, adolescents, and adults (male and female) **9–26** years of age, the ACIP recommends HPV vaccination at age **11 or 12** years, although vaccination can be initiated at **9** years of age.

- For women, **cervical cancer screening** should continue according to age-specific guidelines **regardless of having received an HPV vaccine**
- HPV vaccines are **not licensed** for use in adults **older than 45 years** of age
- HPV infection occurs soon **after first sexual activity** in most people, and vaccine effectiveness is therefore lower in older individuals due to prior infections.
- HPV exposure usually **decreases among older** age groups. Although HPV vaccination is safe for adults **27–45** years of age, the benefit to the population is likely to be minimal. However, some men and women who are not vaccinated may be at risk for acquisition of new HPV infections and could therefore benefit from HPV vaccination.

- HPV vaccines are prophylactic (i.e., they prevent new HPV infections). They have no utility in preventing established HPV infection from progressing to clinical disease, and they do not have a role in treatment of HPV-associated disease.

HPV vaccines are safe in PEOPLE LIVING WITH HIV(PLWH) but antibody levels are generally lower

immune responses appear stronger among PLWH who have the highest CD4 counts and the lowest HIV viral loads

SCREENING FOR HPV-ASSOCIATED CANCER

- screening for cervical cancer is widely accepted as cost-effective in preventing cervical cancer.
- Anal screening is accepted for screening in high-risk groups
- American Society of Colposcopy and Cervical Pathology (ASCCP) guidelines recommend initiation of cervical cancer screening at age 21
- Women 21–29 years old should have a Pap smear every 3 years if their initial and subsequent Pap smears are normal.
- As a method of determining the need for colposcopy, HPV DNA co-testing is recommended for women 25–29 years of age in whom cytology detects abnormal squamous cells of undetermined significance (ASCUS)

- Women 30–65 should have a Pap smear every 3 years if testing for HPV DNA is not performed.
- The screening interval for women in this age group can be extended to every 5 years if HPV DNA co-testing is performed and results are negative
- A positive result for HPV type 16 or 18 has a high enough positive predictive value in the general population that these women should have colposcopy performed.

- Women with evidence of HPV-associated cervical disease should be referred to a gynecologist familiar with HPV and experienced in colposcopy
- For anal or perianal lesions, cryotherapy or surgical removal is safest and most effective. **Anoscopy and/or sigmoidoscopy** should be performed in patients with perianal lesions, and suspicious lesions should be biopsied to rule out malignancy

Key Clinical Pearls for Counseling

The following evidence-based points address the most common clinical misconceptions and counseling challenges encountered in practice.

Sexual Contact is the Only Significant Transmission Route

Genital HPV types 6 and 11 are transmitted **exclusively through sexual activity**. Patients need not fear casual contact with family members, coworkers, or household contacts.

Asymptomatic Individuals Can and Do Transmit HPV

The absence of visible warts does not indicate absence of infection or infectivity. **Subclinical shedding** is well-documented; all sexually active patients should practice safe sex regardless of symptom status.

Wart Removal Does Not Clear HPV Infection

Treatment targets the **visible lesion, not the underlying virus**. HPV may persist in surrounding tissue after successful wart removal; recurrence is common and should be anticipated and discussed pre-treatment.

HPV Types 6 & 11 Do Not Cause Cancer

A crucial reassurance: the types responsible for genital warts are **low-risk, non-oncogenic**. Distinguish clearly from high-risk types (16, 18) when counseling patients to reduce disproportionate cancer anxiety.

Vaccination is Beneficial Even After Prior Exposure

Prior HPV infection does not preclude vaccination benefit. Patients may not have been exposed to all vaccine-covered types; vaccination is recommended **regardless of prior HPV history**.

Immunocompromised Patients Need Closer Follow-Up

HIV-positive, transplant, or otherwise immunosuppressed patients are at **higher risk for persistent, recurrent, and extensive warts**. More frequent surveillance and aggressive management are warranted in this population.

Instagram: **dr.Zahra.seghatoleslami**

